Abstract
Cytokines are reported to be associated with the formation of prostate cancer. Our aim was to investigate whether C/T polymorphisms of the interleukin‐2 (IL‐2) gene and IL‐2 receptor beta (IL‐2RB) gene are associated with prostate cancer. We compared the frequency of the polymorphisms of the IL‐2 gene and the IL‐2RB gene between 96 patients with prostate cancer and 105 healthy male volunteers from the same area (age >60 years). They were followed for at least 5 years. There was a significant difference in distribution of the genotype of the IL‐2 gene polymorphism between the prostate cancer group and the control group (P = 0.017). The distribution of the TT homozygote of the IL‐2 gene was significantly higher in the cancer group (32.3%) than in the control group (16.2%). However, no significant statistical difference was found between the polymorphism of the IL‐2 gene and prostate cancer in survival analysis during a 5‐year follow up period (log rank test; P = 0.19). There was no significant difference in the distribution of the genotype of the IL‐2RB gene polymorphism between controls and cancer patients (P = 0.388). This study suggests that the IL‐2 gene may be associated with susceptibility to prostate cancer in the Taiwan population. J. Clin. Lab. Anal. 20:245–249, 2006. © 2006 Wiley‐Liss, Inc.
Keywords: interleukin‐2 gene (IL‐2), interleukin‐2 receptor gene (IL‐2 R), prostate cancer, single nucleotide polymorphisms (SNPs)
REFERENCES
- 1. Harris DT, Matyas GR, Gomella LG, et al. Immunologic approaches to the treatment of prostate cancer. Semin Oncol 1999;26:439–447. [PubMed] [Google Scholar]
- 2. Dolman CS, Mueller BM, Lode HN, Xiang R, Gillies SD, Reisfeld RA. Suppression of human prostate carcinoma metastases in severe combined immunodeficient mice by interleukin 2 immunocytokine therapy. Clin Cancer Res 1998;4:2551–2257. [PubMed] [Google Scholar]
- 3. Horak I. Immunodeficiency in IL‐2‐knockout mice. Clin Immunol Immunopathol 1995;76:S172–S173. [DOI] [PubMed] [Google Scholar]
- 4. Matesanz F, Fedetz M, Collado‐Romero M, et al. Allelic expression and interleukin‐2 polymorphisms in multiple sclerosis. J Neuroimmunol 2001;119:101–105. [DOI] [PubMed] [Google Scholar]
- 5. Sadlack B, Lohler J, Schorle H, et al. Generalized autoimmune disease in interleukin‐2‐deficient mice is triggered by an uncontrolled activation and proliferation of CD4+T cells. Eur J Immunol 1995;25:3053–3059. [DOI] [PubMed] [Google Scholar]
- 6. Royuela M, De Miguel MP, Bethencourt FR, Fraile B, Arenas MI, Paniagua R. IL‐2, its receptors, and bcl‐2 and bax genes in normal, hyperplastic and carcinomatous human prostates: immunohistochemical comparative analysis. Growth Factors 2000;18:135–146. [DOI] [PubMed] [Google Scholar]
- 7. Matesanz F, Alcina A, Pellicer A. A new cDNA sequence for the murine interleukin‐2 gene. Biochim Biophys Acta 1992;1132:335–336. [DOI] [PubMed] [Google Scholar]
- 8. Matesanz F, Alcina A, Pellicer A. Existence of at least five interleukin‐2 molecules in different mouse strains. Immunogenetics 1993;38:300–303. [DOI] [PubMed] [Google Scholar]
- 9. Matesanz F, Alcina A. Induction of autoantibodies to different interleukin‐2 allotypes. J Autoimmun 1999;12:221–227. [DOI] [PubMed] [Google Scholar]
- 10. Matesanzl F, Delgado C, Fresno M, Alcinal A. Allelic selection of human IL‐2 gene. Eur J Immunol 2000;30:3516–3521. [DOI] [PubMed] [Google Scholar]
- 11. Aus G, Abbou CC, Pacik D, et al. EAU guidelines on prostate cancer. Eur Urol 2001;40:97–101. [DOI] [PubMed] [Google Scholar]
- 12. Moody DB, Robinson JC, Ewing CM, Lazenby AJ, Isaacs WB. Interleukin‐2 transfected prostate cancer cells generate a local antitumor effect in vivo. Prostate 1994;24:244–251. [DOI] [PubMed] [Google Scholar]
- 13. Hrouda D, Dalgleish AG. Gene therapy for prostate cancer. Gene Ther 1996;3:845–852. [PubMed] [Google Scholar]
- 14. Belldegrun A, Tso CL, Zisman A, et al. Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology. Hum Gene Ther 2001;12:883–892. [DOI] [PubMed] [Google Scholar]
- 15. Triest JA, Grignon DJ, Cher ML, et al. Systemic interleukin 2 therapy for human prostate tumors in a nude mouse model. Clin Cancer Res 1998;4:2009–2014. [PubMed] [Google Scholar]
- 16. Hautmann SH, Huland E, Huland H. Local intratumor immunotherapy of prostate cancer with interleukin‐2 reduces tumor growth. Anticancer Res 1999;19:2661–2663. [PubMed] [Google Scholar]
- 17. Lloyd SN, McClinton S, Brown IL, et al. Epidermal growth factor receptor, nuclear proliferation antigen and interleukin‐2 receptor expression in prostatic cancer. J Clin Lab Immunol 1990;32:55–58. [PubMed] [Google Scholar]